Filamin A binding proteins and uses thereof
AssigneeBerg LLC
InventorsWenfang Sybil Wu, Shobha Ravipaty, Tracey Friss, Viatcheslav R. Akmaev, Nikunj Narendra Tanna
Life of this patent
Estimating the term…
Abstract
The present invention encompasses filamin A (FLNA) binding proteins. Specifically, the invention relates to antibodies to FLNA. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention in methods of diagnosis, monitoring and prognosis of prostate cancer are also provided.
Claims30
An antibody, or antigen-binding fragment thereof, capable of binding filamin A (FLNA), comprising
- a heavy chain variable region comprising a CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 9, a CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 8, and a CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 7;
- and
- a light chain variable region comprising a CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 12, a CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 11, and a CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 10.
An antibody, or antigen-binding fragment thereof, capable of binding filamin A (FLNA), comprising
- a heavy chain variable region comprising a CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 15, a CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 14, and a CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 13;
- and
- a light chain variable region comprising a CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 18, a CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 17, and a CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 16.
An antibody, or antigen-binding fragment thereof, capable of binding filamin A (FLNA), comprising
- a heavy chain variable region comprising a CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 21, a CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 20, and a CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 19;
- and
- a light chain variable region comprising a CDR3 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 24, a CDR2 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 23, and a CDR1 domain comprising the amino acid sequence set forth in SEQ ID NO:
- 22.
Dependencies are inferred from the claim text.